Sandbox ap: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(43 intermediate revisions by 3 users not shown)
Line 1: Line 1:
==Diagnostic Criteria==
====Classification Gastritis==
▸ Diagnosis is established by the presence of two of the three following criteria:<ref name="Banks-2013">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Bollen | first2 = TL. | last3 = Dervenis | first3 = C. | last4 = Gooszen | first4 = HG. | last5 = Johnson | first5 = CD. | last6 = Sarr | first6 = MG. |last7 = Tsiotos | first7 = GG. | last8 = Vege | first8 = SS. | last9 = Acosta | first9 = JM. | title = Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. | journal = Gut | volume = 62 | issue = 1 | pages = 102-11 | month = Jan | year = 2013 |doi = 10.1136/gutjnl-2012-302779 | PMID = 23100216 }}</ref>
{| class="wikitable"
* '''Abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe epigastric pain often radiating to the back).'''
!colspan="2" | Gastritis
<!--
!Etiology
::* A dull, colicky pain located in the lower abdomen suggests an alternative etiology.
!Gasstritis synonyms
-->
|-
* '''Serum [[lipase]] or [[amylase]] ≥ 3 x ULN.'''
|colspan="2" | Non-atrophic
<!--
|
::* Amylase may be falsely elevated in [[appendicitis]], [[cholecystitis]], [[intestinal obstruction]] or [[Mesenteric ischemia|ischemia]], [[perforated ulcer]], [[salivary gland]] disease, gynecological disease, renal disease, and [[macroamylasemia]].
*Helicobacter pylori
::* Amylase may remain normal on admission in cases caused by alcohol and [[hypertriglyceridemia]], which occurs in as many as one-fifth of patients.<ref name="Clavien-1989">{{Cite journal  | last1 = Clavien | first1 = PA. | last2 = Robert | first2 = J. | last3 = Meyer | first3 = P. | last4 = Borst | first4 = F. | last5 = Hauser | first5 = H. | last6 = Herrmann | first6 = F. | last7 = Dunand | first7 = V. | last8 = Rohner | first8 = A. | title = Acute pancreatitis and normoamylasemia. Not an uncommon combination. | journal = Ann Surg | volume = 210 | issue = 5 | pages = 614-20 | month = Nov | year = 1989 | doi =  | PMID = 2479346 }}</ref><ref name="Winslet-1992">{{Cite journal  | last1 = Winslet | first1 = M. | last2 = Hall | first2 = C. | last3 = London | first3 = NJ. | last4 = Neoptolemos | first4 = JP. | title = Relation of diagnostic serum amylase levels to aetiology and severity of acute pancreatitis. | journal = Gut | volume = 33 | issue = 7 | pages = 982-6 | month = Jul | year = 1992 | doi =  | PMID = 1379569 }}</ref>
*Other factors
::* Lipase may be falsely elevated in [[appendicitis]], [[cholecystitis]], renal disease, and macrolipasemia.
|
-->
Superficial
* '''Characteristic findings on contrast-enhanced [[computed tomography|CT]], [[magnetic resonance imaging|MRI]], or transabdominal [[ultrasonography|US]].'''
Diffuse antral gastritis (DAG)
<!--
Chronic antral gastritis (CAG)
::* If abdominal pain strongly suggests acute pancreatitis but pancreatic enzyme is less than three times the upper limit of normal, a confirmatory imaging is required.<ref name="Bollen-2007">{{Cite journal  | last1 = Bollen | first1 = TL. | last2 = van Santvoort | first2 = HC. | last3 = Besselink | first3 = MG. | last4 = van Es | first4 = WH. | last5 = Gooszen | first5 = HG. | last6 = van Leeuwen | first6 = MS. | title = Update on acute pancreatitis: ultrasound, computed tomography, and magnetic resonance imaging features. | journal = Semin Ultrasound CT MR | volume = 28 | issue = 5 | pages = 371-83 | month = Oct | year = 2007 | doi =  | PMID = 17970553 }}</ref><ref name="Morgan-2008">{{Cite journal  | last1 = Morgan | first1 = DE. | title = Imaging of acute pancreatitis and its complications. | journal = Clin Gastroenterol Hepatol | volume = 6 | issue = 10 | pages = 1077-85 | month = Oct | year = 2008 | doi = 10.1016/j.cgh.2008.07.012 | PMID = 18928934 }}</ref>
Interstitial - follicular
::* If the diagnosis is established by abdominal pain and elevated pancreatic enzyme, a CECT is not usually required on admission.
Hypersecretory
-->
Type B*
|-
|rowspan="4" |Atrophic
|Autoimmune
|
*Autoimmunity
|
Type A*
Diffuse corporal
Pernicious anemia-associated
|-
|rowspan="3"|Multifocal atrophic
|Helicobacter pylori
|Type B*, type AB*
|-
|Dietary
|Environmental
|-
|Environmental factors
|Metaplastic
|-
|rowspan="7"| Special form
|rowspan="4"| Chemical
|Chemical irritation
|Reactive
|-
|
*Bile
|
*Reflux
|-
|
*NSAIDs
|
*NSAID
|-
|
*Other agents
|
*Type C*
|-
|Radiation
|Radiation injury
|
|}


<div class="mw-collapsible mw-collapsed">
==Risk assessment table==
{|
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Scoring criteria for risk assessment*
|-
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Scoring system
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Score
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Risk
|-
| rowspan="14" style="background:#DCDCDC;" align="center" + |'''IMPROVEDD Score'''<ref>{{cite journal|doi=10.1055/s-0037-160392910.1055/s-0037-1603929}}</ref>
| style="background:#DCDCDC;" align="center" + |
| style="background:#DCDCDC;" align="center" + |Predicted % VTE risk through 42 days
|-
| style="background:#F5F5F5;" align="center" + |0
| style="background:#F5F5F5;" + |0.4%
|-
| style="background:#F5F5F5;" align="center" + |1
| style="background:#F5F5F5;" + |0.6%
|-
| style="background:#F5F5F5;" align="center" + |2
| style="background:#F5F5F5;" + |0.8%
|-
| style="background:#F5F5F5;" align="center" + |3
| style="background:#F5F5F5;" + |1.2%
|-
| style="background:#F5F5F5;" align="center" + |4
| style="background:#F5F5F5;" + |1.6%
|-
| style="background:#F5F5F5;" align="center" + |5-10
| style="background:#F5F5F5;" + |2.2%
|-
| style="background:#DCDCDC;" align="center" + |
| style="background:#DCDCDC;" align="center" + |Predicted % VTE risk through 77 days
|-
| style="background:#F5F5F5;" align="center" + |0
| style="background:#F5F5F5;" + |0.5%
|-
| style="background:#F5F5F5;" align="center" + |1
| style="background:#F5F5F5;" + |0.7%
|-
| style="background:#F5F5F5;" align="center" + |2
| style="background:#F5F5F5;" + |1.0%
|-
| style="background:#F5F5F5;" align="center" + |3
| style="background:#F5F5F5;" + |1.4%
|-
| style="background:#F5F5F5;" align="center" + |4
| style="background:#F5F5F5;" + |1.9%
|-
| style="background:#F5F5F5;" align="center" + |5-10
| style="background:#F5F5F5;" + |2.75
|-
| rowspan="7" style="background:#DCDCDC;" align="center" + |'''IMPROVE score'''<ref name="pmid21436241">{{cite journal| author=Spyropoulos AC, Anderson FA, Fitzgerald G, Decousus H, Pini M, Chong BH et al.| title=Predictive and associative models to identify hospitalized medical patients at risk for VTE. | journal=Chest | year= 2011 | volume= 140 | issue= 3 | pages= 706-14 | pmid=21436241 | doi=10.1378/chest.10-1944 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21436241  }} </ref>
| style="background:#DCDCDC;" align="center" + |
| style="background:#DCDCDC;" align="center" + |Predicted % VTE risk through 3 months
|-
| style="background:#F5F5F5;" align="center" + |0
| style="background:#F5F5F5;" + |0.5%
|-
| style="background:#F5F5F5;" align="center" + |1
| style="background:#F5F5F5;" + |1.0%
|-
| style="background:#F5F5F5;" align="center" + |2
| style="background:#F5F5F5;" + |1.7%
|-
| style="background:#F5F5F5;" align="center" + |3
| style="background:#F5F5F5;" + |3.1%
|-
| style="background:#F5F5F5;" align="center" + |4
| style="background:#F5F5F5;" + |4%
|-
| style="background:#F5F5F5;" align="center" + |5-8
| style="background:#F5F5F5;" + |11%
|-
| rowspan="2" style="background:#DCDCDC;" align="center" + | '''Padua Score'''<ref name="pmid20738765">{{cite journal| author=Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M et al.| title=A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. | journal=J Thromb Haemost | year= 2010 | volume= 8 | issue= 11 | pages= 2450-7 | pmid=20738765 | doi=10.1111/j.1538-7836.2010.04044.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20738765  }} </ref>
| style="background:#F5F5F5;" align="center" + |< 4
| style="background:#F5F5F5;" + |Low risk for VTE
|-
| style="background:#F5F5F5;" align="center" + |≥ 4
| style="background:#F5F5F5;" + |High risk for VTE
|-
| rowspan="4" style="background:#DCDCDC;" align="center" + |'''Caprini score'''<ref name="pmid1754886">{{cite journal| author=Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F| title=Clinical assessment of venous thromboembolic risk in surgical patients. | journal=Semin Thromb Hemost | year= 1991 | volume= 17 Suppl 3 | issue=  | pages= 304-12 | pmid=1754886 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1754886  }} </ref>
| style="background:#F5F5F5;" align="center" + |0-1
| style="background:#F5F5F5;" + |Low risk of VTE
|-
| style="background:#F5F5F5;" align="center" + |2
| style="background:#F5F5F5;" + |Moderate of VTE
|-
| style="background:#F5F5F5;" align="center" + |3-4
| style="background:#F5F5F5;" + |High risk of VTE
|-
| style="background:#F5F5F5;" align="center" + |≥ 5
| style="background:#F5F5F5;" + |Highest risk for VTE
|}
 
==Images ILD==
<gallery widths=200px>
 
F2.large.jpg | Cellular Players and Molecules in IPF <br> [http://err.ersjournals.com/content/24/135/102.full<font size="-2">''Adapted from European Respiratory Review''</font>]
 
</gallery>
<gallery widths=200px>
 
1-s2.0-S0272523112000044-gr6.jpg | Flow Chart for Lung Fibrosis Evaluation in ILD <br> [http://http://www.sciencedirect.com/science/article/pii/S0272523112000044/ <font size="-2">''Adapted from Clinics in Chest Medicine''</font>]
 
</gallery>
 
==Widget==
 
 
<div class="nomobile">
<div style="position:right; width:50%; float:right; background-color:#d0d0d0; border-radius: 10px;"><span style="position:right; float:right; width: 100%;"><center>'''Tweets by NEJM!'''<hr>{{#Widget:NEJM}}</center>
</span></div>
</div>
 
<br style="clear:right" />
 
==References==

Latest revision as of 16:03, 16 May 2018

==Classification Gastritis

Gastritis Etiology Gasstritis synonyms
Non-atrophic
  • Helicobacter pylori
  • Other factors

Superficial Diffuse antral gastritis (DAG) Chronic antral gastritis (CAG) Interstitial - follicular Hypersecretory Type B*

Atrophic Autoimmune
  • Autoimmunity

Type A* Diffuse corporal Pernicious anemia-associated

Multifocal atrophic Helicobacter pylori Type B*, type AB*
Dietary Environmental
Environmental factors Metaplastic
Special form Chemical Chemical irritation Reactive
  • Bile
  • Reflux
  • NSAIDs
  • NSAID
  • Other agents
  • Type C*
Radiation Radiation injury

Risk assessment table

Scoring criteria for risk assessment*
Scoring system Score Risk
IMPROVEDD Score[1] Predicted % VTE risk through 42 days
0 0.4%
1 0.6%
2 0.8%
3 1.2%
4 1.6%
5-10 2.2%
Predicted % VTE risk through 77 days
0 0.5%
1 0.7%
2 1.0%
3 1.4%
4 1.9%
5-10 2.75
IMPROVE score[2] Predicted % VTE risk through 3 months
0 0.5%
1 1.0%
2 1.7%
3 3.1%
4 4%
5-8 11%
Padua Score[3] < 4 Low risk for VTE
≥ 4 High risk for VTE
Caprini score[4] 0-1 Low risk of VTE
2 Moderate of VTE
3-4 High risk of VTE
≥ 5 Highest risk for VTE

Images ILD

Widget

Tweets by NEJM!


References

  1. ↑ . doi:10.1055/s-0037-160392910.1055/s-0037-1603929. Missing or empty |title= (help)
  2. ↑ Spyropoulos AC, Anderson FA, Fitzgerald G, Decousus H, Pini M, Chong BH; et al. (2011). "Predictive and associative models to identify hospitalized medical patients at risk for VTE". Chest. 140 (3): 706–14. doi:10.1378/chest.10-1944. PMID 21436241.
  3. ↑ Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M; et al. (2010). "A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score". J Thromb Haemost. 8 (11): 2450–7. doi:10.1111/j.1538-7836.2010.04044.x. PMID 20738765.
  4. ↑ Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F (1991). "Clinical assessment of venous thromboembolic risk in surgical patients". Semin Thromb Hemost. 17 Suppl 3: 304–12. PMID 1754886.
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox_ap&oldid=1471341"